Eduardo Vianna

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.

NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland.